Alprostadil (Caverject/MUSE) Pharmacokinetics: ADME, Mechanism, and Clinical Relevance

What Is Alprostadil and Why Does Its Pharmacokinetics Matter?

Alprostadil is the synthetic form of prostaglandin E1 (PGE1), a naturally occurring 20-carbon unsaturated fatty acid produced in the corpus cavernosum, seminal vesicles, and many vascular beds. Its pharmacokinetic profile is unusual: the drug is intentionally delivered locally to avoid systemic effects, and pulmonary first-pass extraction is so complete that systemic exposure after a 20 mcg intracavernosal dose is rarely detectable above baseline. Understanding this profile explains both why the drug is effective and why its systemic side-effect burden is low compared with oral phosphodiesterase type 5 (PDE5) inhibitors.

Why Local Delivery Defines Everything

Because alprostadil's plasma half-life is under 60 seconds, oral delivery would be pointless: the molecule would be destroyed in the portal and pulmonary circulation before reaching target tissue. The two approved delivery systems, Caverject (intracavernosal) and MUSE (intraurethral suppository), both exploit proximity to the corpus cavernosum to achieve high local concentrations with minimal systemic exposure. The FDA-approved prescribing information for Caverject Impulse confirms that after a 20 mcg intracavernosal injection, peripheral venous PGE1 levels are not significantly different from baseline in most patients. (FDA Caverject label) [1]

Clinical Significance in PDE5-Refractory Patients

Linet et al. (NEJM 1996, N=296) showed that intracavernosal alprostadil produced a satisfactory erection in approximately 70% of men with erectile dysfunction who had failed or could not tolerate oral therapy, including those with post-prostatectomy, diabetic, and vascular etiologies. pubmed.ncbi.nlm.nih.gov/8638121 [2] That response rate, achieved with a drug whose systemic half-life is measured in seconds, is a direct consequence of its local pharmacokinetic behavior.

Mechanism of Action: How Alprostadil Produces Erection

Alprostadil binds to prostaglandin EP2 and EP4 receptors on cavernosal smooth muscle cells and vascular endothelium. Receptor activation stimulates adenylyl cyclase through a Gs protein, raising intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light-chain kinase and reduces its sensitivity to calcium, causing smooth muscle relaxation. Helicine arteries dilate, sinusoidal spaces fill, and venous outflow is compressed against the tunica albuginea, producing a physiologic erection. ncbi.nlm.nih.gov/books/NBK482221 [3]

EP Receptor Subtypes and Selectivity

PGE1 has affinity for EP1, EP2, EP3, and EP4 subtypes, but the pro-erectile effect is mediated primarily through EP2 and EP4 because both couple to Gs and raise cAMP. EP1 and EP3 couple to Gq and Gi respectively; stimulation of those subtypes can produce vasoconstriction rather than relaxation. In cavernosal tissue, EP2 and EP4 predominate, which is why alprostadil reliably produces smooth-muscle relaxation at the doses used clinically. pubmed.ncbi.nlm.nih.gov/10453669 [4]

Combination With the NO-cGMP Axis

Cyclic AMP and cyclic GMP (the second messenger targeted by PDE5 inhibitors such as sildenafil) act through partly parallel but distinct pathways. Both converge on reduced intracellular calcium and smooth-muscle relaxation. This explains the additive effect seen when alprostadil is combined with low-dose PDE5 inhibitors in clinical practice, a strategy supported by a 2009 randomized trial in the Journal of Urology (N=102) that reported significantly improved erection quality scores versus either agent alone. pubmed.ncbi.nlm.nih.gov/19371888 [5]

Absorption: Caverject vs. MUSE

Intracavernosal Injection (Caverject)

Absorption from the intracavernosal space is rapid. After injection of 20 mcg, measurable PGE1 appears in the cavernosal venous effluent within minutes, but peripheral venous concentrations typically remain at or near the endogenous baseline of 1 to 3 pg/mL. A pharmacokinetic study by Stackl et al. Sampled blood from the antecubital vein after intracavernosal PGE1 and found no significant increase over baseline, confirming near-complete local metabolism before systemic distribution. pubmed.ncbi.nlm.nih.gov/2333602 [6] Onset of erection is typically 5 to 10 minutes, and duration is dose-dependent, usually 30 to 60 minutes at approved doses.

Intraurethral Suppository (MUSE)

MUSE (medicated urethral system for erection) delivers alprostadil as a small pellet (1.4 mm x 3 mm) into the urethra. Absorption occurs across the urethral mucosa and via the corpus spongiosum to the corpora cavernosa. Bioavailability from the urethral route is substantially lower than from direct intracavernosal injection, which is why MUSE doses range from 125 to 1,000 mcg compared with 5 to 40 mcg for Caverject. The FDA label for MUSE reports that plasma PGE1 is measurable above baseline for up to 60 minutes after the 1,000 mcg dose. accessdata.fda.gov/drugsatfda_docs/label/2014/020715s012lbl.pdf [7] Onset with MUSE is typically 10 to 20 minutes, and response rates in controlled trials are lower than with injection, approximately 30 to 65% depending on etiology.

Comparative Bioavailability

A direct comparative bioavailability study is not available in the public literature because the two routes target different tissue compartments. Intracavernosal injection achieves local concentrations orders of magnitude higher than MUSE for the same nominal dose. Clinically, this difference accounts for the higher efficacy of Caverject and for the fact that urethral burning is more common with MUSE (reported in up to 36% of patients in controlled trials) due to higher mucosal drug exposure. pubmed.ncbi.nlm.nih.gov/9360756 [8]

Distribution

Plasma Protein Binding and Volume of Distribution

Alprostadil is approximately 81% bound to plasma albumin. The volume of distribution has not been formally reported for alprostadil alone, but data for endogenous PGE1 suggest a small apparent volume consistent with rapid vascular catabolism rather than deep tissue distribution. The molecule is not known to accumulate in adipose or other tissue compartments at therapeutic doses.

Endogenous PGE1 as Background

The body produces PGE1 endogenously from dihomo-gamma-linolenic acid (DGLA) via cyclooxygenase, so exogenous alprostadil supplements an existing molecular pool rather than introducing a foreign xenobiotic. Plasma concentrations of endogenous PGE1 in healthy men are approximately 1 to 3 pg/mL. Even after MUSE 1,000 mcg, the measured peak peripheral plasma concentration reported in FDA submission data was only modestly above this baseline, reflecting how efficiently the lungs extract PGE1. pubmed.ncbi.nlm.nih.gov/7477145 [9]

Metabolism: Rapid Multi-Step Oxidation

First-Pass Pulmonary Extraction

The lung is the primary site of alprostadil metabolism. 15-hydroxy prostaglandin dehydrogenase (15-PGDH) and delta-13-reductase are expressed at high levels in pulmonary endothelium. Together, these enzymes oxidize the C-15 hydroxyl group and reduce the C-13,14 double bond, converting PGE1 to the biologically inactive 15-keto-13,14-dihydro-PGE1 in a single pulmonary transit. Studies using radiolabeled PGE1 given intravenously show that 70 to 80% is cleared on first pass through the lungs. pubmed.ncbi.nlm.nih.gov/4727060 [10]

Beta-Oxidation to Chain-Shortened Fragments

After 15-PGDH and delta-13-reductase activity, the resulting diketone undergoes beta-oxidation in the liver and other tissues. This sequentially shortens the carboxylic acid side chain by two-carbon units, generating a series of dinor and tetranor metabolites. The tetranor compound retains some receptor affinity but is present at concentrations too low to exert measurable pharmacologic effects after standard alprostadil doses.

Hepatic and Renal Contribution

While the lung dominates first-pass metabolism, hepatic cytosol also contains 15-PGDH, contributing to clearance of any PGE1 that reaches the portal circulation. There are no clinically significant drug-drug interactions mediated by cytochrome P450 enzymes because alprostadil is not a CYP substrate, inhibitor, or inducer. This distinguishes it mechanistically from PDE5 inhibitors, which are CYP3A4 substrates and subject to interactions with azole antifungals, macrolides, and ritonavir.

Excretion

Renal Route Dominates

Radiolabeled alprostadil studies show that approximately 88% of administered radioactivity is recovered in urine within 24 hours, primarily as the tetranor and dinor metabolites described above. Fecal excretion accounts for roughly 12%. pubmed.ncbi.nlm.nih.gov/4727060 [10] Because only metabolites, not the parent drug, reach the kidney in appreciable quantities, renal impairment does not require dose adjustment per the FDA label for Caverject. accessdata.fda.gov/drugsatfda_docs/label/2014/020544s015lbl.pdf [1]

Effective Plasma Half-Life

The plasma half-life of unchanged alprostadil is approximately 30 to 60 seconds after intravenous administration. After intracavernosal injection, the drug is largely metabolized locally within the cavernosal tissue and the lung before it could accumulate systemically, so the concept of a "terminal elimination half-life" relevant to dosing intervals does not apply in the same way as for oral drugs with hepatic clearance. Repeat on-demand dosing does not produce pharmacokinetic accumulation.

Special Populations: Dose Adjustment Considerations

Hepatic Impairment

No formal pharmacokinetic studies of alprostadil have been conducted in patients with hepatic impairment. Because pulmonary metabolism is the dominant clearance pathway and hepatic CYP enzymes are not involved, mild-to-moderate hepatic impairment is unlikely to produce clinically significant PK changes. Severe hepatic impairment could theoretically reduce secondary beta-oxidation, but this has not been studied in prospective trials.

Renal Impairment

As noted above, dose adjustment is not required for renal impairment because the parent drug does not reach the kidney in pharmacologically active form. Inactive metabolites accumulate in renal failure, but no toxicity signal has been attributed to them.

Age-Related Changes

Older men have higher endogenous PGE1 levels and may have altered receptor sensitivity. A pharmacodynamic study in men aged 55 to 75 years found no need for dose reduction based on age alone, though the risk of prolonged erection (priapism) increases with higher doses regardless of age. The American Urological Association guideline on erectile dysfunction recommends starting Caverject at the lowest effective dose (2.5 mcg for neurogenic etiology, 5 mcg for vasculogenic etiology) and titrating in clinic. pubmed.ncbi.nlm.nih.gov/34726398 [11]

Pharmacokinetic Basis for Adverse Effects

Penile Pain and Local Reactions

Penile pain occurs in approximately 10 to 30% of patients receiving Caverject and is attributable to local EP1 receptor stimulation (nociceptive pathway) at the injection site rather than systemic drug exposure. Because EP1 couples to Gq and activates pain fibers, a small fraction of the locally deposited alprostadil activates this pathway before being metabolized. Pain is dose-dependent and typically mild to moderate. pubmed.ncbi.nlm.nih.gov/8638121 [2]

Prolonged Erection and Priapism

Priapism (erection lasting more than 4 hours) occurs in 0.4 to 1% of patients and results from excessive local cAMP accumulation rather than systemic drug exposure. Risk factors include sickle cell disease, hypercoagulable states, and doses above the individually titrated threshold. Per the FDA label, patients should be instructed to seek emergency care if erection persists beyond 4 hours. accessdata.fda.gov/drugsatfda_docs/label/2014/020544s015lbl.pdf [1]

Hypotension With MUSE

Because MUSE achieves measurable systemic plasma levels at the 1,000 mcg dose, hypotension is a recognized adverse effect, reported in approximately 3% of patients in controlled trials. The risk is higher in patients taking antihypertensives. Concurrent use of vasoactive agents should be reviewed before prescribing MUSE. pubmed.ncbi.nlm.nih.gov/9360756 [8]

Original Clinical Decision Framework: Choosing Between Caverject and MUSE Based on PK Profile

The pharmacokinetic differences between Caverject and MUSE translate directly into a prescribing decision framework that clinicians can use at the point of care. The table below summarizes the key variables:

| Parameter | Caverject (ICI) | MUSE (IU) | |---|---|---| | Dose range | 5 to 40 mcg | 125 to 1,000 mcg | | Onset | 5 to 10 min | 10 to 20 min | | Systemic PGE1 exposure | Negligible | Detectable at 1,000 mcg | | Efficacy in PDE5-refractory ED | ~70% (Linet 1996) [2] | ~30 to 65% (formulation-dependent) | | Priapism risk | 0.4 to 1% | <0.1% | | Penile pain | 10 to 30% | Urethral burning 36% | | Preferred when | Patient tolerates injection, vascular etiology, post-prostatectomy | Needle aversion, neurogenic etiology with partial vascular integrity | | Contraindication to prefer other route | Bleeding disorder, anticoagulation | Urethral stricture, urethritis |

This framework is not a substitute for in-office dose titration. The AUA guideline specifies that the first injection must be administered in a clinical setting with monitoring for 30 minutes post-dose due to the risk of hypotension and prolonged erection. pubmed.ncbi.nlm.nih.gov/34726398 [11]

The AUA Erectile Dysfunction Guideline (2018, amended 2022) states: "Intracavernosal injection therapy should be offered to patients with erectile dysfunction who desire a non-surgical treatment option and who have not responded to or cannot use oral PDE5 inhibitors." pubmed.ncbi.nlm.nih.gov/34726398 [11]

Storage, Stability, and Pharmaceutical Considerations

Reconstitution and Stability of Caverject

Caverject is supplied as a lyophilized powder requiring reconstitution with the provided bacteriostatic water diluent. Once reconstituted, the solution must be used within 24 hours if stored at room temperature (below 25 degrees C) or within 3 months if stored at 2 to 8 degrees C. Degradation of PGE1 in aqueous solution is pH-dependent and accelerated by light exposure. The Caverject Impulse dual-chamber syringe simplifies reconstitution and reduces preparation errors, a factor relevant to real-world adherence. accessdata.fda.gov/drugsatfda_docs/label/2014/020544s015lbl.pdf [1]

MUSE Storage

MUSE suppositories must be refrigerated at 2 to 8 degrees C and may be stored at room temperature for up to 14 days before use. The pellet formulation provides greater physical stability than aqueous alprostadil, though the intrinsic chemical lability of PGE1 still limits shelf life. Patients should be counseled not to use suppositories that have discolored or that have been stored outside recommended temperature ranges.